Robert Schreiber

Robert Schreiber pioneered the concept of cancer immunoediting, describing how tumors escape immune surveillance through antigen loss and MHC class I downregulation. His work established that beta-2-microglobulin loss causes complete MHC class I surface loss, rendering tumor cells invisible to cytotoxic T cells and resistant to checkpoint immunotherapy. His three-phase immunoediting model (elimination, equilibrium, escape) remains the foundational framework for understanding IO resistance. His laboratory continues to identify targetable mechanisms of immune escape.